[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"autonomic-dysreflexia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:autonomic-dysreflexia":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,44,64,88,119,144,165,192],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100593876","deciphering-preserved-autonomic-function-after-multiple-sclerosis-100593876",false,"NCT07012135","Deciphering Preserved Autonomic Function After Multiple Sclerosis","DPAF-MS","Inclusion Criteria:\n\n* 18-50 years old\n* clinically confirmed diagnosis of multiple sclerosis -OR- uninjured control\n\nExclusion Criteria:\n\n* symptoms of cardiovascular (including, but not limited to: hypertension, stroke, chest pain, etc.), respiratory, peripheral neurological or autonomic disease (particularly diabetes mellitus requiring treatment)\n* women who are pregnant or lactating\n* having a body mass index (BMI) ≥ 35 kg\u002Fm2\n* taking or being administered a medication known to potentially have adverse interactions with phenylephrine\n* in the judgement of the principal investigator or clinical collaborator, any illness or condition that will interfere with the patient's ability to comply with the protocol, compromise patient safety, or interfere with the interpretation of the study results",true,"ALL","18 Years","50 Years",{"count":21,"type":22},13,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study looks to characterize gradients of dysfunction in the autonomic nervous system in patients with clinically diagnosed multiple sclerosis. The autonomic nervous system plays key roles in regulation of blood pressure, skin blood flow, and bladder health- all issues that individuals with multiple sclerosis typically suffer. Focusing on blood pressure regulation, the most precise metric with broad clinical applicability, the investigators will perform laboratory-based tests to probe the body's ability to generate autonomic responses. For both individuals with multiple sclerosis and uninjured controls, laboratory-based experiments will utilize multiple parallel recordings to identify how the autonomic nervous system is able to inhibit and activate signals. The investigators anticipate that those with autonomic dysfunction with multiple sclerosis will exhibit abnormalities in these precise metrics. The investigators will look to see if any substantial connections exist between different degrees of preserved autonomic function and secondary autonomic complications from multiple sclerosis. In accomplishing this, the investigators hope to give scientists important insights to how the autonomic nervous system works after multiple sclerosis and give physicians better tools to manage these secondary autonomic complications.",[28,29,30],"Multiple Sclerosis","Control Subjects","Autonomic Dysreflexia","RECRUITING","2026-05-26",{"date":34,"type":35},"2026-05-28","ACTUAL",{"date":37,"type":35},"2025-09-17",{"date":39,"type":22},"2026-12-31",{"name":41,"class":42},"Mayo Clinic","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":58,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":43},"100400372","deciphering-preserved-autonomic-function-after-spinal-cord-injury-100400372","NCT04493372","Deciphering Preserved Autonomic Function After Spinal Cord Injury","Inclusion Criteria:\n\nAll subjects\n\n\\- age 18-50 years old.\n\nParticipants with spinal cord injury\n\n* Adult onset, traumatic spinal cord injury.\n* American Spinal Injury Association Impairment Scale, A-D, to encompass a spectrum of autonomic dysfunction after spinal cord injury.\n* Neurological level of injury, C1-T12, as defined by the International Standards for Neurological Classification of Spinal Cord Injury. Incorporating level of injury down to T12 to encompass a broad range of autonomic dysfunction.\n\nExclusion Criteria:\n\n* History of cardiovascular disease, hypertension, neurologic disorders (with exception of spinal cord injury), or diabetes.\n* Women who are pregnant or lactating.\n* Currently taking blood thinners.\n* Pacemaker, implanted defibrillator, or intrathecal pump incompatible with MRI scanning.\n* Cognitive issues preventing informed consent for participation.\n* Body mass index \\>30 kg\u002Fm2 for controls, in an effort to limit effects of early cardiovascular disease and diabetes in control population. Body mass index has not proven to be a good estimate of these factors following spinal cord injury.",{"count":51,"type":22},69,[25],"This study looks to characterize gradients of dysfunction in the autonomic nervous system after spinal cord injury. The autonomic nervous system plays key roles in regulation of blood pressure, skin blood flow, and bladder health- all issues that individuals with spinal cord injury typically suffer. Focusing on blood pressure regulation, the most precise metric with broad clinical applicability, the investigators will perform laboratory-based tests to probe the body's ability to generate autonomic responses. For both individuals with spinal cord injury and uninjured controls, laboratory-based experiments will utilize multiple parallel recordings to identify how the autonomic nervous system is able to inhibit and activate signals. The investigators anticipate that those with autonomic dysfunction after spinal cord injury will exhibit abnormalities in these precise metrics. The investigators will further have research participants wear a smart watch that tracks skin electrical conductance, heart rate, and skin temperature, which can all provide clues as to the degree of autonomic dysfunction someone may suffer at home. The investigators will look to see if any substantial connections exist between different degrees of preserved autonomic function and secondary autonomic complications from spinal cord injury. In accomplishing this, the investigators hope to give scientists important insights to how the autonomic nervous system works after spinal cord injury and give physicians better tools to manage these secondary autonomic complications.",[55,56,30,57],"Spinal Cord Injuries","Autonomic Imbalance","Orthostatic Hypotension",{"date":34,"type":35},{"date":60,"type":35},"2020-11-13",{"date":62,"type":22},"2026-09-08",{"name":41,"class":42},{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":23,"phases":73,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":87},"100631697","non-invasive-spinal-cord-stimulation-and-blood-pressure-regulation-after-spinal-cord-injury-100631697","NCT07504055","Non-invasive Spinal Cord Stimulation and Blood Pressure Regulation After Spinal Cord Injury","Effectiveness of Transcutaneous Spinal Cord Stimulation on Blood Pressure Regulation in Individuals With Chronic Spinal Cord Injury","Inclusion Criteria:\n\n* At least 18 years old,\n* Stable medical condition,\n* Non-progression SCI (no negative change in the neurological level and motor-completeness assess during screening when compared to the neurological status assessed at 6-month period after injury or at least 6 months prior to the screening),\n* Motor-complete SCI according to the American Spinal Injury Association (ASIA) Impairment Scale (AIS) grade \"A,\" \"B,\" or \"C\" above T1 spinal level according to the ASIA International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) Neurological Level of Injury (NLI),\n* Sustained SCI at least 12 months prior to entering the study,\n* Evidence of symptomatic hypotension as determined by a total score \\>0 on the Orthostatic Hypotension Symptom Assessment (OSHA),\n* Normal renal function as defined by eGFR \\> 59 ml\u002Fmin\u002F1.73, creatinine value within the range of 0.6-1.2 mg\u002Fdl, and BUN values within the range of 7-18 mg\u002Fdl,\n* Competent to give informed consent for the research protocol,\n* Able to understand instructions.\n\nExclusion Criteria:\n\n* Major pulmonary or cardiovascular disease unrelated to SCI,\n* Ventilator dependence,\n* Painful musculoskeletal dysfunction that might interfere with testing or stimulation,\n* Unhealed fracture that might interfere with testing or stimulation,\n* Unhealed contracture that might interfere with testing or stimulation,\n* Unhealed pressure sore that might interfere with testing or stimulation,\n* Untreated clinically significant depression or psychiatric disorders,\n* Ongoing drug abuse,\n* Malignancy ,\n* Class III obesity (BMI \\>40) and at least one co-morbidity thereof: a) Type 2 diabetes as defined by ≥6.5% level on two separate glycated hemoglobin (A1C) tests, b) hypertension as defined by consistent blood pressure readings of ≥140\u002F90 mmHg or taking medication for blood pressure,\n* Acute or chronic obstructive deep vein thrombosis,\n* Secondary hypotension unrelated to SCI (anemia, hypervolemia, endocrine and neurological diseases),\n* Major esophageal\u002Fgastrointestinal problem,\n* Currently pregnant (females of childbearing potential only),\n* Other major medical illness contraindicated for testing or stimulation.",{"count":72,"type":22},40,[25],"The goal of this clinical trial is to learn if non-invasive spinal cord stimulation intervention improves blood pressure regulation in individuals with chronic spinal cord injury. The main questions it aims to answer are:\n\n* Can site specific spinal cord stimulation enhance blood pressure regulation?\n* Does this stimulation affect enzymes responsible for blood pressure regulation? Researchers will stimulate different sites of spinal cord and compare to see if site-specific stimulation provide blood pressure stability.\n\nParticipants will have up to six pairs of self-adhesive conductive electrodes placed on the skin over the spinal cord (midline and\u002For just to the left and right of midline) as cathodes and up to six pairs of self-adhesive electrodes located symmetrically on the skin over the iliac crests, clavicles, shoulders, and\u002For abdominal muscles (left and right of the umbilicus) as anodes for stimulation of the spinal cord.",[76,77,30],"Spinal Cord Injury","Orthostatic Hypertension","2026-04-27",{"date":80,"type":35},"2026-04-28",{"date":82,"type":35},"2026-04-01",{"date":84,"type":22},"2029-02",{"name":86,"class":42},"University of Louisville",2,{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":17,"minAge":95,"maxAge":96,"enrollmentInfo":97,"targetDuration":4,"studyType":23,"phases":99,"briefSummary":101,"conditions":102,"keywords":103,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":4},"100488110","phase-2-no-ad-use-of-nitric-oxide-no-donors-for-the-prevention-of-autonomic-dysreflexia-ad-during-bowel-care-following-sci-100488110","NCT05635851","NO AD: Use of Nitric Oxide (NO) Donors for the Prevention of Autonomic Dysreflexia (AD) During Bowel Care Following SCI","NO AD","Inclusion Criteria:\n\n* participants must have had a traumatic spinal cord injury at least one year ago\n* regular bowel care routine\n* can communicate in English\n\nExclusion Criteria:\n\n* cauda equina or conus lesions\n* currently use ventilator\n* colostomy, or do not perform regular bowel care\n* skin breakdown (pressure sores)\n* cannot communicate in English\n* under 19 years old\n* possibly or certainly pregnant\n* medical\u002Fpsychiatric condition or substance abuse that is likely to affect ability to complete study\n* currently using medications containing PDE-5 inhibitors\n* currently using medications containing GTN\n* allergy to GTN","19 Years","80 Years",{"count":98,"type":22},26,[100],"PHASE2","This project aims to evaluate the safety and efficacy of using a short-acting drug to reduce the maximal blood pressure during dangerous blood pressure spikes that happen during bowel care in individuals with spinal cord injury. the investigators will monitor the physiological effects of this drug during at-home bowel care to best understand the drug's effects in typical use.",[55,30],[104,105,106,107,108],"spinal cord injury","autonomic dysreflexia","blood pressure","bowel care management","defecation","NOT_YET_RECRUITING","2026-04-22",{"date":112,"type":35},"2026-04-23",{"date":114,"type":22},"2026-12",{"date":116,"type":22},"2028-02",{"name":118,"class":42},"Simon Fraser University",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":129,"phases":4,"briefSummary":130,"conditions":131,"keywords":4,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":43},"100628060","cardiac-morphology-and-function-in-individuals-with-autonomic-dysreflexia-100628060","NCT07456722","Cardiac Morphology and Function in Individuals With Autonomic Dysreflexia","Assessment of Cardiac Morphology and Function in Individuals With and Without Autonomic Dysreflexia Due to Spinal Cord Injury or Disease","HEART_REMOD_AD","Inclusion Criteria:\n\n* adults aged 18 years or older\n* long-term (\\>10 years), motor-complete SCI\u002FD (AIS A and B)\n* Group A (24 individuals): high-level (\\>Th6) SCI\u002FD and autonomic dysreflexia\n* Group B (24 individuals): low-level (\\\u003CTh10) SCI\u002FD without autonomic dysreflexia\n* signed informed consent\n\nExclusion Criteria:\n\n* congenital heart defects\n* valvular disease(s)\n* cardiomyopathy\n* medium to severe arrhythmia\n* myocardial infarction\n* comorbidities causing morphologic heart changes including primary hypertension, aortic stenosis\n* comorbidities causing arterial hypertension\n* use of anti-hypertensive treatment\n* smokers\n* individuals after sacral deafferentation surgery\n* pregnancy\n* active implanted medical devices\n* claustrophobia\n* inability to comply with the measurement procedures",{"count":128,"type":22},48,"OBSERVATIONAL","This case-control study aims to investigate left ventricular remodeling in individuals with chronic spinal cord injury or disease (SCI\u002FD) (≥10 years) and autonomic dysreflexia (AD) who have no prior cardiovascular history. The primary objective is to compare cardiac changes between 24 individuals with high-level SCI\u002FD (above Th6) who have AD and 24 individuals with low-level SCI\u002FD (below Th10) who do not have AD. A secondary objective examines how factors such as age, sex, injury duration, and physical activity are associated with cardiac remodeling.\n\nAll 48 participants will undergo cardiac MRI as well as blood measurement of B-type natriuretic peptid to assess cardiac morphology and function. The findings could shed light on a potentially underestimated cardiovascular risk factor in the SCI\u002FD population.",[30,132,133],"Spinal Cord Injuries and Disorders (SCI\u002FD)","Cardiac Remodeling","2026-03-09",{"date":136,"type":35},"2026-03-11",{"date":138,"type":22},"2026-05-01",{"date":140,"type":22},"2028-10-31",{"name":142,"class":143},"Swiss Paraplegic Research, Nottwil","NETWORK",{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":129,"phases":4,"briefSummary":153,"conditions":154,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":43},"100532337","autonomic-dysreflexia-in-spinal-cord-injuries-uds-filling-speed-impact-100532337","NCT06211491","Autonomic Dysreflexia in Spinal Cord Injuries: UDS Filling Speed Impact","Autonomic Dysreflexia Clinical Characteristics According to the Filling Speed in Urodynamics in Individuals With Spinal Cord Injuries","Inclusion Criteria:\n\n1. Patients with chronic spinal cord injury 6 months after receiving the award\n2. Patients with confirmed AD due to bladder fullness in previous urodynamic test\n3. Patients confirmed to have neurological damage level C1-T6, AIS A or B\n\nExclusion Criteria:\n\n1. Patients who cannot perform the test because their systolic blood pressure remains at 150 mmHg during the urodynamic test\n2. Patients who cannot undergo testing due to hemodynamic instability\n3. Patients who cannot undergo testing due to overt urinary tract infection",{"count":152,"type":22},30,"In patients with spinal cord injury, the investigators want to understand and understand the differences in AD prevalence and characteristics according to bladder injection rate, and to determine which factors have a greater influence between bladder expansion or injection rate.",[55,30,155],"UDS Filling Speed","2026-01-12",{"date":158,"type":35},"2026-01-14",{"date":160,"type":35},"2025-01-08",{"date":162,"type":22},"2026-12-30",{"name":164,"class":42},"Pusan National University Yangsan Hospital",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":17,"minAge":95,"maxAge":172,"enrollmentInfo":173,"targetDuration":4,"studyType":23,"phases":174,"briefSummary":175,"conditions":176,"keywords":181,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":87},"100467649","non-invasive-spinal-cord-stimulation-for-recovery-of-autonomic-function-after-spinal-cord-injury-100467649","NCT05369520","Non-invasive Spinal Cord Stimulation for Recovery of Autonomic Function After Spinal Cord Injury","Non-invasive Spinal Cord Stimulation for Recovery of Autonomic Function After Spinal Cord Injury: Moving From Mechanisms to Clinical Practice","Inclusion Criteria:\n\n1. Resident of British Columbia, Canada with active provincial medical services plan.\n2. Male or female, 19-60 years of age.\n3. Chronic traumatic SCI (non-progressive, with complete motor paralysis) at or above the T6 spinal segment.\n4. \\>1-year post injury, at least 6 months from any spinal surgery.\n5. American Spinal Injury Association Impairment Scale (AIS) A, B.\n6. Stable management of spinal cord related clinical issues (i.e., spasticity management).\n7. Experience bladder, or bowel, or sexual dysfunction.\n8. No painful musculoskeletal dysfunction, unhealed fracture, pressure sore, or active infection that may interfere with testing.\n9. For women of childbearing potential, not intending to become pregnant, currently pregnant, or lactating. The following conditions apply:\n\n   1. A confirmed negative pregnancy test prior to the baseline visit. During the trial, all women of childbearing potential will undergo urine pregnancy tests at their monthly clinic visits as outlined in the schedule of events.\n   2. Use adequate contraception, or complete abstinence from sexual activities, during the period of the trial and for at least 28 days after completion of treatment.\n   3. If using combined hormonal contraception, a stable regimen during the period of the trial and for at least 28 days after completion of treatment.\n10. For sexually active males with female partners of childbearing potential, use adequate contraception, or complete abstinence from sexual activities, during the period of the trial and for at least 28 days after completion of treatment.\n11. Must provide informed consent.\n12. Willing and able to comply with all clinic visits and study-related procedures.\n13. Able to understand and complete study-related questionnaires (must be able to understand and speak English or have access to an appropriate interpreter as judged by the investigator).\n\nExclusion Criteria:\n\n1. Ventilator dependent.\n2. Signs of lower motor neuron damage (i.e. concomitant conus medullaris\u002Fcauda equina injury).\n3. Severe anemia or hypovolemia as measured by hematocrit via blood test in the last six months.\n4. History of cardiovascular, respiratory, bladder, or renal disease unrelated to SCI or presence of hydronephrosis or presence of obstructive renal stones.\n5. History of seizures\u002Fepilepsy or recurring headaches.\n6. Clinically significant, unmanaged, depression (to be screened) or ongoing drug abuse.\n7. Intrathecal baclofen pump.\n8. Oral baclofen dose greater than 60mg.\n9. Individuals that have received intradetrusor or intrasphincter onabotulinumtoxinA injections within 6 months of baseline.\n10. Any implanted metal (other than dental implants) in the skull or presence of pacemakers, stimulators, or medication pumps in the trunk.\n11. Past electrode implantation surgery.\n12. Member of the investigational team or his\u002Fher immediate family.\n13. Presence of severe acute medical issue and use of any specific medication or treatment that, in the investigator's judgement, would adversely affect the participant's participation in the study.\n14. Known allergies or sensitivities to both blue dye and beetroot powder.\n15. Known or suspected gastrointestinal obstruction.\n16. Persons with active inflammatory bowel disease or a history of bowel perforation.","60 Years",{"count":152,"type":22},[25],"This study is a pilot clinical trial to explore the efficacy of transcutaneous spinal cord stimulation (TCSCS) (proof-of-concept) in mitigating crucial autonomic dysfunctions that impact the health-related quality of life of individuals with spinal cord injury (SCI).",[76,177,178,179,180,30,57],"Autonomic Dysfunction","Sexual Dysfunction","Neurogenic Bladder Dysfunction","Neurogenic Bowel Dysfunction",[182,76],"Neurostimulation","2025-12-01",{"date":185,"type":35},"2025-12-08",{"date":187,"type":35},"2023-10-03",{"date":189,"type":22},"2027-10",{"name":191,"class":42},"University of British Columbia",{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":196,"acronym":197,"eligibilityCriteria":198,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":172,"enrollmentInfo":199,"targetDuration":4,"studyType":23,"phases":201,"briefSummary":202,"conditions":203,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":43},"100466291","mild-intermittent-hypoxia-a-prophylactic-for-autonomic-dysfunction-in-individuals-with-spinal-cord-injuries-100466291","NCT05351827","Mild Intermittent Hypoxia: A Prophylactic for Autonomic Dysfunction in Individuals With Spinal Cord Injuries","MIH and AD","Inclusion Criteria:\n\n1. Age 18-60\n2. Motor incomplete spinal cord injury at or above the 12th thoracic vertebrae\n3. Signs or symptoms of autonomic dysfunction (this will be determined by the ADFSCI and ISAFSCI questions. The ADFSCI requires a score of 1 on questions 16 and 22, and the ISAFSCI requires a score of 1 on any parameter)\n4. Chronic injuries (\\> 1 year post injury)\n\nExclusion Criteria:\n\n1. Pregnant\n2. Smoker\n3. Drug addiction\n4. \\\u003C18 or \\>60 years of age\n5. Complete spinal cord injury\n6. Spinal cord injury below the 6th thoracic vertebrae\n7. Insulin dependent diabetes\n8. Shift workers (ie disrupted circadian rhythm)\n9. Active skin breakdown or pressure sores",{"count":200,"type":22},24,[25],"The prevalence of autonomic dysfunction and sleep disordered breathing (SDB) is increased in individuals with spinal cord injury (SCI). The loss of autonomic control results in autonomic dysreflexia (AD) and orthostatic hypotension (OH) which explains the increase in cardiovascular related mortality in these Veterans. There is no effective prophylaxis for autonomic dysfunction. The lack of prophylactic treatment for autonomic dysfunction, and no best clinical practices for SDB in SCI, are significant health concerns for Veterans with SCI. Therefore, the investigators will investigate the effectiveness of mild intermittent hypoxia (MIH) as a prophylactic for autonomic dysfunction in patients with SCI. The investigators propose that MIH targets several mechanisms associated with autonomic control and the co-morbidities associated with SDB. Specifically, exposure to MIH will promote restoration of homeostatic BP control, which would be beneficial to participation in daily activities and independence in those with SCI.",[55,30],"2025-09-16",{"date":206,"type":35},"2025-09-22",{"date":208,"type":35},"2022-10-01",{"date":210,"type":22},"2026-10-29",{"name":212,"class":213},"VA Office of Research and Development","FED"]